key: cord-0953952-qemuhp11
authors: Romano, S.; Frantzen, T.; LaVecchia, G.; Wang, J.
title: 188: Cystic fibrosis kidney stone disease in the era of CFTR modulator use and the COVID-19 pandemic
date: 2021-11-30
journal: Journal of Cystic Fibrosis
DOI: 10.1016/s1569-1993(21)01613-1
sha: 667fa6dfa3ef6aa4a7342a2124e642409595a66f
doc_id: 953952
cord_uid: qemuhp11

nan

Background: CF lung transplant (LT) recipients may warrant treatment with elexacaftor/tezacaftor/ivacaftor to improve extrapulmonary manifestations. We aimed to identify reasons for prescribing elexacaftor/tezacaftor/ ivacaftor after LT and for cessation of elexacaftor/tezacaftor/ivacaftor, issues with immunosuppression management, and observed effects on BMI, hemoglobin A1c, hemoglobin, and liver function tests (LFTs). Methods: This was an electronic health record-based cohort study, October 2019-September 2020, at all 15 CF LT consortium sites in North America. Inclusion criterion: CF LT recipient prescribed elexacaftor/ tezacaftor/ivacaftor after transplant. Data from the 6 months prior and up to 6 months after elexacaftor/tezacaftor/ivacaftor prescription were abstracted by local research coordinators, and clinical details were confirmed with local LT and CF physicians as needed. Statistics: Paired t test was used to assess change from before to after elexacaftor/tezacaftor/ ivacaftor. All consortium sites obtained local IRB approval. Results: Of the 15 sites, 12 sites had LT recipients who were prescribed elexacaftor/tezacaftor/ivacaftor after transplant; 3 sites had zero patients on elexacaftor/tezacaftor/ivacaftor. There was substantial center to center variability in prescribing practices across the 12 sites, with a median of 14% (range 1-35%; IQR 7-29%) of CF LT recipients prescribed elexacaftor/ tezacaftor/ivacaftor. There were 96 total patients prescribed elexacaftor/ tezacaftor/ivacaftor, of whom 87 actually received elexacaftor/tezacaftor/ ivacaftor. Prescriptions were written by CF physicians (41%), LT physicians (24%), or physicians who practice both CF and LT (35%). The average patient age was 38 years (SD 8.9; range 22-63 yrs); 42% were male. The median time from LT to the start of elexacaftor/tezacaftor/ivacaftor was 4.1 years (IQR 1.8, 6.5; range 0.05-25.4 yrs). The median time from starting to stopping elexacaftor/tezacaftor/ivacaftor, for the 34 people who stopped, was 67 days (IQR 25, 150; range 4, 323 days). The most common indications for prescribing elexacaftor/tezacaftor/ivacaftor were sinus disease (67%), GI symptoms (35%), low BMI (19%), chronic lung allograft dysfunction/being considered for re-transplant (12%), and diabetes (10%). Patient preference to try elexacaftor/tezacaftor/ivacaftor was a factor in prescribing for 42% of patients. After starting elexacaftor/tezacaftor/ivacaftor, 4 of 87 patients (5%) required multiple blood tests to stabilize the immunosuppression level and dose. Elexacaftor/tezacaftor/ivacaftor was associated with improved BMI among 17 patients with initial BMI < 18.5 kg/m 2 or low BMI as an indication for elexacaftor/tezacaftor/ivacaftor (+0.5 kg/m 2 , P = 0.045). Elexacaftor/tezacaftor/ivacaftor was associated with a decrease in hemoglobin A1c for 35 patients with pre-and post-elexacaftor/ tezacaftor/ivacaftor A1c values overall (−0.4%, P = 0.002) and for 16 patients with initial A1c >6.5% or diabetes as an indication for elexacaftor/ tezacaftor/ivacaftor (−0.9%, P = 0.001). Elexacaftor/tezacaftor/ivacaftor was associated with an increase in hemoglobin for 65 patients with preand post-elexacaftor/tezacaftor/ivacaftor hemoglobin values (+0.34 g/dL, P = 0.03) and for 45 patients with anemia prior to elexacaftor/tezacaftor/ ivacaftor (+0.6 g/dL, P = 0.006). There was no association of elexacaftor/ tezacaftor/ivacaftor with change in LFTs for 66 patients with pre-and postelexacaftor/tezacaftor/ivacaftor LFT values. Elexacaftor/tezacaftor/ivacaftor was stopped in 41% of cases, most frequently for GI complaints or abdominal pain, while 5% felt no benefit; 32% remained off elexacaftor/ tezacaftor/ivacaftor during the observation period. Conclusion: Nearly 100 CF LT recipients have been prescribed elexacaftor/ tezacaftor/ivacaftor, but a third stopped taking it due to side effects or lack of perceived benefit. For some patients, the benefits were significant: increased BMI for those with low BMI; increased hemoglobin (most notable for those with anemia); decreased A1c. Further study is warranted to determine whether elexacaftor/tezacaftor/ivacaftor can improve clinically meaningful outcomes for CF LT recipients and to identify the appropriate indications and time points for use in the subset of transplant recipients who may benefit. Acknowledgements: CFLTC Study Group.

188 Cystic fibrosis kidney stone disease in the era of CFTR modulator use and the COVID-19 pandemic S. Romano 1 , T. Frantzen 1 , G. LaVecchia 1 , J. Wang 1 . 1 Pulmonology, Northwell Health, New Hyde Park, USA Background: Our adult cystic fibrosis (CF) center has seen an increased prevalence in kidney stones among CF patients over the course of the COVID-19 pandemic, leading us to study this phenomenon, focusing on food choices during strict social isolation and use of highly effective modulator therapy (HEMT). Standard nutritional practice recommends high-calorie, -fat, andsodium diets for people with CF to compensate for fat malabsorption and calorie expenditure related to respiratory status. In the era of HEMT, we hypothesize that excess salt intake in the setting of improved sweat chloride may lead to increased risk for kidney stones. Fat malabsorption related to nonadherence with pancreatic enzyme replacement therapy (PERT) may also contribute to stone formation. We aim to determine risk factors associated with kidney stone disease in CF patients in the setting of possible dietary changes during the COVID-19 pandemic and the use of HEMT. Methods: We performed a retrospective observational study between March and December 2020, examining kidney stone prevalence and risk factors in our CF center. Collected data included body mass index, gastrointestinal symptoms, PERT adherence, and use of CFTR modulators, oral or intravenous antibiotics, and antacids. The CF dietitian administered food intake questionnaires to assess dietary habits and any changes in relation to the time of kidney stones diagnosis and the COVID-19 pandemic. Results: This study included 10 CF patients, ranging from age 23 to 65. A total of 5 patients were newly diagnosed with kidney stones, while the remainder had pre-existing kidney stone history. Stone compositions were as follows: 7 patients had calcium oxalate stones, 1 with uric acid stones, and 2 were unknown. CFTR modulators were prescribed to 9 out of 10 patients, 7 of which were elexacaftor/tezacaftor/ivacaftor. All patients were pancreatic insufficient and prescribed PERT, of which 40% were found to be inconsistently adherent. Across all patients we noticed an increased intake of sodium and animal protein during the COVID-19 pandemic. Several patients also reported reduced water intake with increased consumption of sweetened beverages. Conclusion: New advancements in CF treatments and improved life expectancy support the need for reevaluation of nutritional recommendations as they relate to HEMT use and kidney stone prevention. This is the first study to our knowledge that examined the effect of diet, HEMT, and PERT use on the risk of kidney stones in CF patients. Risk factors identified, such as increased intake of sodium and animal protein in the setting of HEMT, decreased water intake, and inconsistent adherence to PERT, all yield paramount implications as to how CF patients should be guided from a nutritional standpoint. More studies are warranted to determine other risk factors for kidney stone disease in people with CF. Background: In order to optimize nutritional outcomes, youth with CF often require a higher calorie and higher fat diet compared to the general population to maintain a healthy weight. The clinical focus on weight and diet exists against the backdrop of an intense societal focus on being thin. These clinical goals and societal pressures are at odds and may lead youth with CF to experience challenges with body image and disordered eating. Further, there are new challenges with the introduction of highly effective genetic modulator therapies that routinely lead to weight gain. There is evidence of a higher risk of eating disorders in chronic illnesses that require dietary treatment, for example, diabetes mellitus, though preliminary work in youth with CF has shown mixed results, and no screening tools have been validated in patients with CF. Given that eating and digestive issues have been found to be important problems affecting quality of life, more investigation is needed. Methods: Eligible patients with CF aged 14-35 years receiving care at a single CF center were recruited via email to complete the following 3 validated surveys at one point in time: 1) Eating Disorder Examination Questionnaire (EDE-Q), 2) Nine-Item Avoidant/Restrictive Food Intake Disorder Scale (NIAS), and 3) Cystic Fibrosis Questionnaire-Revised (CFQ-R). Descriptive statistics include count and percentage for categorical questions and mean and standard deviations for continuous questions. Univariate linear regression analysis was used to identify baseline risk factors that are associated with the EDE-Q global score, NIAS total score, and each CFQ-R subscale. Based on these univariate results, the variables with univariate P < 0.20 were considered for inclusion in a multivariable linear regression model. Backwards stepwise linear regression was used to identify the final model which includes variables that are significant at the P < 0.05 level. Results: A total of 52 patients (33 females, 19 males) ranging in age from 18 to 35 (mean age 24 years) completed the surveys. Both the mean global EDE-Q score (0.89), and the mean total NIAS score (7.67) were similar to averages in the general population. The prevalence of eating disorder, defined as a global EDE-Q score of 2.3 or greater, was 9.6% (95% exact binomial CI: 3.2%, 21.0%). The CFQ-R eating (−0.196, P = 0.005) and weight (0.141, p < 0.001) subscales were significant risk factors for higher score in the EDE-Q in the final model. CFQ-R eating subscale (−1.863, p < 0.001) and being dF508 homozygous (4.305, P = 0.006) were found to be significantly correlated with a higher NIAS total score. Conclusion: Although the mean scores on both the EDE-Q and NIAS were similar to population means, a significant proportion of our CF patients screened positive for an eating disorder. Eating and weight scales of the CFQ-R were associated with these general population screeners. Further work is needed to better understand the optimal way to use such tools to screen and treat for eating disorders in those with CF. Acknowledgements: Funded by: CF Foundation (KASS 20D0).

Creation of a nutrition report for cystic fibrosis patients B. Besore 1 , S. Peterson 1 , K. Nowak 2 . 1 Clinical Nutrition, Rush University, Chicago, USA; 2 Food and Nutrition, Rush University Medical Center, Chicago, USA Background: Patients with cystic fibrosis (CF) often have difficulty meeting estimated calorie and vitamin intake goals. A nutrition report is a potential interventional tool clinicians and dietitians could use to efficiently and effectively present nutrition status and recommendations. With this tool, we would hope to improve patients' BMI percentile, adherence to pancreatic enzyme treatment, and management of fat-soluble vitamin status. The objective of this quality improvement project was to determine content validity of a nutrition report for pediatric CF patients. Methods: A nutrition report was developed to provide patients with an overview of their nutritional status. The report contained data obtained from the electronic medical record and CF Smart Reports to populate 6 sections: 1) nutritionally relevant medications ( pancreatic enzyme replacement therapy, gastric acid suppressing agent), 2) caloric intake recommendations (estimated daily calorie requirement and use of dietary supplements or enteral nutrition), 3) weight status (trend of body mass index [BMI], BMI percentile, weight percentile, and height percentile), 4) vitamin levels (including prescribed vitamin supplement and a trend of yearly measured levels), 5) previous visit nutrition goals, and 6) current visit action plan. A mock nutrition report was created and used to assess content validity. A content validity questionnaire was created to determine if reviewers agreed, somewhat agreed, somewhat disagreed, or disagreed that the material included in the nutrition report was clear, relevant, organized, and visually appealing. An open-ended question was included to allow reviewers to list their main take-away message from the presented report and to list any comments. The item context validity index (I-CVI) was calculated by diving the number of experts in agreement by the total number of experts to assess the content validity. The report was considered to have content validity with an average CVI >0.78. Two different groups, the inter-professional CF team and a convenience sample of CF dietitians, assessed the content validity. Results: The report was distributed to a total of 11 clinicians on the interprofessional CF team; 64% completed the content validity questionnaire. The average CVI from the CF team was 0.98, confirming the report had content validity. A total of 8 CF dietitians completed the content validity questionnaire (80% response rate). The average CVI from the CF dietitians was 0.95, confirming content validity. Feedback from both the team and the CF dietitians fell into 3 main categories: logistical information, additions to the report, and alterations to make the report more patient friendly; specifically, finalizing where the report will be stored, how it will be delivered within the clinic workflow, wording changes, tracking stool history, and adding the patient's future gastrointestinal or endocrine appointments. Conclusion: Overall, this report is an individualized tool that patients can use to improve their nutritional status. In an ideal world this report would be clear and understandable to patients and the dietitian would have ample time to update this report before each clinic; however, the sustainability of this report needs to be assessed to fit the needs of the RUMC CF Clinic.

Assessment of vitamin supplementation knowledge in adults with cystic fibrosis C. Ziegler 1 , S. Peterson 1 , K. Nowak 2 . 1 Clinical Nutrition, Rush University, Chicago, USA; 2 Food and Nutrition, Rush University Medical Center, Chicago, USA Background: Cystic fibrosis (CF) is a genetic disease caused by a mutation to the CF transmembrane regulator (CFTR) gene, which leads to dysfunctional movement of chloride into cells. Multiple therapies are required to manage CF, which in turn can lead to poor adherence. The majority of individuals with CF are prescribed a high-dose, fat-soluble vitamin (D, A, E, K) supplement to ensure appropriate vitamin levels. However, minimal data is available to describe patient knowledge and barriers to adherence to vitamin supplementation. The goal of this quality

To treat or not to treat: CFTR modulators after lung transplantation

The extrapulmonary effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis